The final months of 2025 could mark a defining chapter in Zymeworks Inc.'s (ZYME) story. With topline data from the HERIZON-GEA-01 trial expected before year-end, the company stands on the cusp of a potential breakthrough in HER2-positive gastroesophageal adenocarcinoma (GEA), a notoriously aggressive cancer with limited first-line treatment options.
At the heart of this moment is zanidatamab, a bispecific antibody engineered to target HER2 with dual precision. If the trial delivers, it won't just validate the molecule's therapeutic promise, it could signal a new era for Zymeworks, one where royalty streams and global access converge to reshape its long-term strategy.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com